GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (FRA:978) » Definitions » Institutional Ownership

Adagene (FRA:978) Institutional Ownership : 0.02% (As of Sep. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Adagene Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adagene's institutional ownership is 0.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adagene's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adagene's Float Percentage Of Total Shares Outstanding is 0.00%.


Adagene Institutional Ownership Historical Data

The historical data trend for Adagene's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagene Institutional Ownership Chart

Adagene Historical Data

The historical data trend for Adagene can be seen below:

2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31
Institutional Ownership 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02

Adagene Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Adagene Business Description

Traded in Other Exchanges
Address
Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Adagene Headlines

No Headlines